title: [Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología].
abstract: Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-specific antigen (PSA) measurement are diagnostic tests available for general practitioners that allow setting a correct BPH diagnose. Patients with an IPSS<8 should be monitored by evaluating them annually. Treatment with alpha-blockers and an evaluation at the first and third month is recommended in patients with an IPSS 8-20 and if the prostate is small, if the prostate size is large treatment with alpha-blockers or 5alpha-reductase inhibitors and evaluation at the third and six month is recommended, and in patients with a large prostate and a PSA >1.5 ng/ ml combined treatment and evaluation at the first and sixth month is recommended. Some clear criteria for referral to urology are established in this document, which help in the management of these patients. Those patients with BPH who do not show any improvement at the third month of treatment with alpha-blockers, or the sixth month with 5alpha-reductase inhibitors, will be referred to urology. Patients will also be referred to urology if they have lower urinary tract symptoms, a pathological finding during rectal examination, IPSS>20, PSA>10 ng/ml or PSA>4 ng/ml and free PSA<20% or if they are <50 years with suspected BHP, or if they have any urological complication.
authors.affiliation: Hospital Universitario Virgen Macarena, Sevilla, España. uro-cast@us.es
authors.forename: J
authors.initials: J
authors.lastname: Castiñeiras Fernández
authors.forename: J M
authors.initials: JM
authors.lastname: Cozar Olmo
authors.forename: A
authors.initials: A
authors.lastname: Fernández-Pro
authors.forename: J A
authors.initials: JA
authors.lastname: Martín
authors.forename: F J
authors.initials: FJ
authors.lastname: Brenes Bermúdez
authors.forename: E
authors.initials: E
authors.lastname: Naval Pulido
authors.forename: J M
authors.initials: JM
authors.lastname: Molero
authors.forename: D
authors.initials: D
authors.lastname: Pérez Morales
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000465:Algorithms; D003937:Diagnosis, Differential; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D011320:Primary Health Care; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D011471:Prostatic Neoplasms / Q000175:diagnosis; D011472:Prostatitis / Q000175:diagnosis; D012017:Referral and Consultation / Q000592:standards*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D017430:Prostate-Specific Antigen